PRNewswire

• HANSIZHUANG (serplulimab) is the world's first anti-PD-1 mAb for first-line treatment of ES- SCLC  -
• HANSIZHUANG (serplulimab) is expected to become the first and only anti-PD-1 monoclonal antibody available in Europe for first-line treatment of ES- SCLC  -
• HANSIZHUANG (serplulimab) has already been approved in China, Indonesia, Cambodia, and Thailand, benefiting around 80,000 patients

SHANGHAI, Sept. 21, 2024 /PRNewswire/ -- Shanghai Henlius Biotech, Inc.... (continue reading...)

NEW DELHI, Sept. 21, 2024 /PRNewswire/ -- Translumina was incorporated in 2011 as a sales & marketing company specialising in coronary intervention devices. Since its inception, the company has successfully established their own manufacturing capabilities and developed in-house product lines, which are endorsed by interventional cardiologists worldwide.

NEW YORK, Sept. 21, 2024 /PRNewswire/ -- The longing for peace transcends time, geography and religion. Based on justice, human rights and universal values outlined in the UN Charter, a culture of peace brings us all together in our common agenda for humanity. We can only co-exist by aligning ourselves with such a world order.

On today's International... (continue reading...)

- Celebrate Charity Day and Chuseok with JungKwanJang's Tesla Giveaway and Give a Gift of Health Initiative

CERRITOS, Calif., Sept. 20, 2024 /PRNewswire/ -- Cerritos, CA - Korea Ginseng Corp. US (KGCUS) aka JungKwanJang is celebrating two significant occasions this September: the International Day of Charity and Chuseok, Korea's Thanksgiving. In honor of both events, JungKwanJang is launching two exciting campaigns—a Tesla Model 3 Giveaway with over 180 prizes and the... (continue reading...)

VANCOUVER, BC, Sept. 20, 2024 /PRNewswire/ - LiTHOS Group Ltd. ("LiTHOS" or the "Company") (CBOE CA: LITS) (OTCQB: LITSF) (FSE: YU8) (WKN: A3ES4Q), today announces an important update to its executive and management compensation strategy. In a strategic move to preserve capital and align leadership with the Company's long-term success, the LiTHOS Board has approved the grant of Restricted Share Units (RSUs) and Performance Share Units (PSUs) to its management and key... (continue reading...)